



Flexion Therapeutics, Inc.
 Investor Relations Department
 10 Mall Road
 Suite 301
 Burlington, MA 01803
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: FLXN	
Last Trade:	19.19
Trade Time:	4:00 PM ET May 22, 2017
Change:	1.57 ↑ (+8.910%)
Day Range	17.74 - 19.35
52-Week Range	10.24 - 29.41
Volume	977,558


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta™ (FX006), is an extended release intra-articular, analgesic candidate in late stage development for moderate to severe osteoarthritis pain.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 22, 2017 [Flexion to Present New Cost-Effectiveness Data on Zilretta™ \(FX006\) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting](#)
- May 18, 2017 [Flexion Therapeutics Announces Upcoming Data Presentation at the American Diabetes Association's 77th Scientific Sessions](#)
- May 4, 2017 [Flexion Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights](#)
- May 1, 2017 [Flexion Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference](#)
- Apr 28, 2017 [Flexion Therapeutics Highlights Two Clinical Data Presentations at the Osteoarthritis Research Society International 2017 World Congress](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 10, 2017 [Annual Report \(10-K\)](#)
- Apr 28, 2017 [Proxy Statement \(DEF 14A\)](#)
- May 5, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 7, 2016 [Quarterly Report \(10-Q\)](#)
- Aug 3, 2016 [Quarterly Report \(10-Q\)](#)